Comparing the Consolidation Regimens of IDA With Intermediate-dose Cytarabine Versus Intermediate-dose Cytarabine Alone for Elderly AML Patients

  • STATUS
    Recruiting
  • participants needed
    320
  • sponsor
    Fujian Medical University
Send
Updated on 16 February 2024
See if I qualify
remission
heart failure
ejection fraction
cytarabine
idarubicin
induction chemotherapy
anthracyclines
myocardial infarction
arrhythmia
leukemia
acute promyelocytic leukemia
infarction

Summary

This study evaluates Idarubicin (IDA) in combination with the intermediate-dose cytarabine, compared with intermediate-dose cytarabine alone, as a consolidation treatment for elderly AML in first remission.

Details
Condition AML in Remission
Age 60years - 75years
Treatment Idarubicin, ID cytarabine
Clinical Study IdentifierNCT04216771
SponsorFujian Medical University
Last Modified on16 February 2024

Eligibility

 Yes No Not Sure

Inclusion Criteria

Newly diagnosed de novo AML who achieved complete remission (CR), including CRi and CRp after a maximum number of 2 cycles of induction chemotherapy
Histologically or morphologically confirmed diagnosis of AML except for AML M3 (acute promyelocytic leukemia)
No contraindication to anthracyclines : decompensated or uncontrolled heart failure, recent myocardial infarction, current signs of cardiac impairment, uncontrolled arrhythmias, LVEF (left ventricular ejection fraction) < 50%
Age 60 years and < 75 years
ECOG performance status 2
Written informed consent
No psychological, familial, social, or geographic reason that would compromise clinical follow up

Exclusion Criteria

Relapsed or refractory AML
Patients with acute promyelocytic leukemia (APL)
Patients with secondary type AML (post myelodysplastic syndrome MDS or therapy-related AML)
Severe pshyciatric or organic disorder, supposed to be independent from AML, that would contraindicate treatment
Subjects for which allogeneic HSCT is planned in CR1
Known allergic or hypersensitivity to idarubicin or cytarabine or to any of the test compounds, materials
Concurrent, uncontrolled medical condition, laboratory abnormality, or psychiatric illness which could place the subject at unacceptable risk
A co-morbid condition which, in the view of the Investigators, renders the subject at high risk from treatment complications
Clear my responses
Read more

How to participate?

Step 1 Connect with a study center
Message sent successfully.
We have submitted the information you provided to the research team at the location you chose. For your records, we have sent a copy of the message to your email address.
If you would like to be informed of other studies that may be of interest to you, you may sign up for Patient Notification Service.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Other language

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Browse trials for

remission
heart failure
ejection fraction
cytarabine
idarubicin
induction chemotherapy
anthracyclines
myocardial infarction
arrhythmia
leukemia
acute promyelocytic leukemia
infarction

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.